70502-03-3

Usage

InChI:InChI=1/C11H11NO2/c1-8-10(7-13)12-11(14-8)9-5-3-2-4-6-9/h2-6,13H,7H2,1H3

Upstream product

• 70501-99-4 5-methyl-4-methylene-2-phenyl-4,5-dihydro-oxazole 
• 70501-97-2 benzimidic acid 1-methyl-prop-2-ynyl ester 
• 61151-96-0 ethyl 5-methyl-2-phenyloxazole-4-carboxylate 

Downstream Products

• 70170-23-9 5-methyl-2-phenyl-1,3-oxazole-4-carboxaldehyde 
• 178610-63-4 4-(2-fluoro-4-nitrophenoxymethyl)-5-methyl-2-phenyloxazole 
• 157169-73-8 2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-nitropyridine 
• 923017-15-6 [2-(benzyloxy)-4-methoxyphenyl]{6-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]pyridin-3-yl}methanone 
• 157169-74-9 5-amino-2-(5-methyl-2-phenyl-4-oxazolylmethoxy)pyridine 
• 159017-79-5 (E)-3-[6-(5-methyl-2-phenyl-4-oxazolylmethoxy)-3-pyridyl]acrylaldehyde 
• 178610-64-5 3-fluoro-4-(5-methyl-2-phenyl-4-oxazolylmethoxy)aniline 
• 166253-88-9 methyl (E)-3-[6-(5-methyl-2-phenyl-4-oxazolylmethoxy)-3-pyridyl]acrylate 
• 178238-83-0 (E)-[3-fluoro-4-(5-methyl-2-phenyl-4-oxazolylmethoxy)]cinnamaldehyde 
• 166253-89-0 (E)-3-[6-(5-methyl-2-phenyl-4-oxazolylmethoxy)-3-pyridyl]-2-propen-1-ol 
• 166253-87-8 methyl 2-bromo-3-[6-(5-methyl-2-phenyl-4-oxazolylmethoxy)-3-pyridyl]propionate 
• 166254-17-7 2-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-5-[3-(1H-tetrazol-5-yl)-propyl]-pyridine 
• 132451-29-7 N-methyl-N-[(5-methyl-2-phenyl-4-oxazolyl)-methyl]amine 
• 132451-31-1 4-methylaminocarbonyl>benzaldehyde 

Relevant academic research and scientific papers

NOVEL COMPOUNDS AS AGONIST FOR PPAR GAMMA AND PPAR ALPHA, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

The present invention relates to novel compounds accelerating the activity of Peroxisome proliferator-activated receptor gamma (PPARγ) and alpha (PPARα), processes of preparing the same, and pharmaceutical compositions containing the same as an active agent.

HETEROCYCLIC COMPOUNDS AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS, USEFUL FOR THE TREATMENT AND/OR PREVENTION OF DISORDERS MODULATED BY A PPAR

The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

Carboxylic acid derivatives and drugs containing the same as the active ingredient

A peroxisome proliferator activated receptor regulator containing a compound of formula (I) (wherein all symbols are as defined in the specification), or a salt thereof as active ingredient. Because of having an effect of regulating PPAR, a compound of fo

Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis

The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazolidinedione analogs that have been designed to include esters within the structure of the compounds are provided. This invention is also drawn to methods of treating disorders, such as diabetes, comprising the administration of therapeutically effective compositions comprising compounds that have been designed to be metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical compositions of the ester-containing thiazolidinedione analogs are also taught.

Substituted oxazoles and thiazoles derivatives as hPPARγ and hPPARα activators

The present invention discloses compounds of formula (I), and tautomeric forms, pharmaceutically acceptable salts, or solvates thereof. Preferably, the compounds of the invention are dual activators of hPPARγ and hPPAR{acute over (α)}.

Thiazolidinedione derivatives as hypoglycemic agents

Hypoglycemic thiazolidine-2,4-dione derivatives of the formula STR1 wherein the dotted line represents a bond or no bond; V is --CH=CH--, --N=CH--, --CH=N--, S, O or NR; W is S, SO, SO2, SO2 NR1, NR1 SO2/s

Novel Thiazolidine-2,4-diones as Potent Euglycemic Agents

A new series of thiazolidine-2,4-diones was obtained by replacing the ether function of englitazone with various functional groups, i.e., a ketone, alcohol, or olefin moiety.These compounds lower blood glucose levels in the genetically obese and insulin-r

Thiazolidinedione derivatives as hypoglycemic agents

Hypoglycemic thiazolidine-2,4-dione derivatives of the formula wherein the dotted line represents a bond or no bond;, V is -CH=CH-, -N=CH-, -CH=N-, S, O or NR;, W is S, SO, SO2, SO2NR1, NR1SO2, CONR1 or NR1CO;, X is S, O,